The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1611
November 16, 2020
View Complete Issue         Table of Contents 2019 
Issue 1611
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
In Brief: Hydrochlorothiazide and Skin Cancer
November 16, 2020 (Issue: 1611)
The FDA has required the addition of information about an increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) to the labels of products containing the diuretic hydrochlorothiazide.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1611
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.